The Psychedelic Evidence Atlas

Introduction

A Molecule Between Worlds

Some substances enter public consciousness through a laboratory. Others arrive through music, friendship, rumour and the stories people tell the morning after. MDMA has travelled through all of those worlds.

To one person, its name may recall a crowded room, a shared rhythm and a feeling of connection that seemed to reach beyond ordinary conversation. To another, it is associated with a difficult night, a medical emergency or concern for someone they love. In research, it appears as a characterised preparation, administered under supervision and measured through interviews, questionnaires and physiological recordings.

These accounts describe different circumstances. Understanding their relationship requires enough room for each of them, and enough discipline to recognise what each can establish. A memory can explain why a question matters without answering it for everyone. A controlled result can tell us something important without explaining the whole experience of the people who took part.

This volume follows MDMA through history, chemistry, subjective effects, harms and therapeutic investigation. Its organising question is how a claim earns its place. What was administered? Who was studied? What changed, compared with what, and over which interval? Those details become especially consequential when an acute experience is proposed as part of a treatment intended to change a life.

The chapters move from history and bodily effects to social experience, harms and clinical research. The final chapters examine follow-up, blinding, professional responsibility and regulation before considering other therapeutic uses.

The distinction between MDMA-assisted therapy and MDMA alone runs throughout that journey. So does the distinction between a defined research preparation and a substance encountered outside that setting. Each chapter keeps the conditions of the observation in view.

Numbered citations refer to the source notes for the chapter in which they appear. Those notes are collected at the back of the book and the numbering starts again in each chapter. They identify study designs, limitations and selected source checks; citation does not imply that every table or supplement was checked. This introduction sets out the approach; the evidence and its sources are developed in the chapters that follow.

The investigation begins with the molecule, before either the dance floor or the consulting room claimed it.

Chapter 1 — Before Ecstasy

At Merck in Darmstadt in 1912, chemist Anton Köllisch produced MDMA as an intermediate in work on haemostatic substances, intended to control bleeding. The company was pursuing a chemical route around a competitor's patent. MDMA was a step towards another compound. [1]

It is a modest beginning for a substance later burdened with such large expectations. The laboratory record establishes that a molecule had been made. It does not establish that its maker recognised the experience someone might have after taking it. Those are different discoveries, separated here by decades and by changes in the questions people were asking.

When we look backwards from a dance floor or a therapy room, the early laboratory can seem like the beginning of an inevitable journey. The documents offer no such destination. They record work undertaken for purposes of its own. Understanding that distance helps us follow what came later without allowing the ending to rewrite the beginning.

Selected landmarks in the history examined here

• 1912 — Köllisch produces MDMA at Merck as a chemical intermediate. [1,2]

• 1953–1954 — MDMA appears in US military animal experiments. [3]

• 1970 — Chicago seizure precedes Shulgin’s documented self-experiments. [5,6]

• 1976–1978 — Shulgin’s self-experiments, introduction to Zeff and publication with Nichols. [6,7]

The medicine that was never the plan

A familiar account says that Merck developed MDMA as an appetite suppressant. Freudenmann, Öxler and Bernschneider-Reif's 2006 archival investigation found no evidence of that plan in records for 1900–1960. It placed MDMA within haemostatic research and suggested that repeated copying helped sustain the mistaken account. [1]

The distinction changes the story. An abandoned appetite suppressant suggests a drug that was evaluated for a purpose and then found wanting. An intermediate might have been made without attracting much pharmacological attention at all. We should not attach a clinical failure to a compound merely because a later summary supplies it with the wrong original job.

A companion paper from the same research group explains that the 1912 patent concerned a chemical procedure, with MDMA as a precursor. It places basic pharmacological testing in 1927, followed by an economic halt and later toxicological work in the 1950s. The historians could not reconstruct the 1927 testing methods; they found no evidence of human administration at Merck in the period examined. [2]

This reconstruction rests on historians' examination of company documents. Citing it does not mean that this book has independently inspected the complete Merck archive. It means the account has a stated evidential basis that can be examined and challenged. The absence of human tests in those records also has a defined scope; it is not proof about every unrecorded event elsewhere.

Different laboratories different questions

Passie and Benzenhöfer place MDMA among mescaline-related compounds explored within the US military’s wider search for substances that could alter behaviour. Their history documents MDMA in secret animal work in 1953–1954. Human experiments with other named compounds in that programme should not be recounted as MDMA experiments. The report does not establish operational use of MDMA. [3]

Hardman, Haavik and Seevers published an animal study in 1973 examining mescaline and seven related compounds, including MDMA, across five species. The work addressed toxicity and behaviour. It was not an investigation of therapeutic relationships or of the personal significance of an experience. [4]

Military interest can give a historical account an atmosphere of hidden knowledge. But interest in a substance is evidence of a research question, not evidence that an institution achieved its ambitions. The phrase truth drug, for example, describes a hoped-for application; it cannot establish that a compound makes statements accurate. Nor can results obtained with a neighbouring chemical automatically become results for MDMA.

A street sample before a famous experiment

By the 1970s, the surviving record extends beyond institutional laboratories. Passie and Benzenhöfer reconstructed this period using forensic records and other historical material. They identify an MDMA seizure in Chicago in 1970 and further detections in the American Midwest during the following years. Their analysis places those events before Shulgin's documented self-experiment in 1976. [5, 6]

That chronology complicates the impression that a therapeutic discovery was subsequently carried out into recreational life. MDMA was already appearing outside formal medicine. The surviving detections do not, however, tell us everything the people involved believed they were buying or making, or how they described its effects.

A forensic identification answers a chemical question about a sample. It cannot, on its own, establish the first human use, the size of a social network or a person's reason for taking the substance. Even a map of detections reflects the places authorities looked and the material they obtained. It is a view through a particular set of windows.

The historians suggest that demand for alternatives to the related drug MDA helped MDMA emerge in underground production after MDA's control in 1970. This is an interpretation of the historical pattern, not a complete account of every producer's motive. [5]

MDA and MDMA need to remain distinct in this history. Similar names can collapse separate events into one apparent sequence. Evidence concerning one substance may supply context for interest in the other, while still leaving its particular effects and risks to be investigated.

What Shulgin helped discover

Alexander Shulgin's role becomes clearer when we specify the contribution. He did not first create the molecule. Benzenhöfer and Passie's examination of his publications and laboratory notebook documents his renewed interest in the mid-1970s and his self-experiments in September and October 1976. They describe his introduction of MDMA to psychotherapist Leo Zeff in 1977 and the publication with David Nichols in 1978 of an early account of its effects in humans. [6]

These events connected several kinds of knowledge. A chemical could be prepared; someone could describe its subjective effects; a therapist could see a possible application; publication could bring the observation to a wider audience. Each connection mattered without requiring one person to have originated the entire history.

There is a reason to resist assigning all of this to a single moment of discovery. The claim can obscure people who encountered the substance earlier and the networks through which information moved. Yet correcting the chronology need not diminish the importance of recognising something in an experience and helping others investigate it. Shulgin's influence belongs in that more precise account.

For Zeff, the question would become what such an experience might make possible in psychological work. That question takes us towards the next chapter. At this point, recognising a possible use was a reason to investigate. It could not yet supply the clinical evidence needed to establish the use.

An early report and its limits

The 1978 chapter by Shulgin and Nichols, Characterization of Three New Psychotomimetics, offers a valuable contemporary view. Its MDMA section describes a state with emotional and sensory qualities and comparatively little hallucinatory activity. It also states that “psychological sequelae are virtually non-existent.” [7]

The sentence records the authors' assessment at the time. It is much broader than a brief exploratory description can establish about uncommon or delayed consequences across different people and circumstances. We should read it as part of the evidence's history, rather than carry it forward as a settled safety conclusion.

The report cites a 1960 synthesis from safrole, without recounting the 1912 Merck records reconstructed by later historians. This illustrates why an original report can be valuable for one question while offering incomplete historical context. The document's account of human effects and the archival reconstruction address different parts of the story. [1, 7]

The next change in meaning

By the late 1970s, MDMA's story already contained pharmaceutical work, animal experiments, underground circulation and emerging interest in psychological use. These developments overlapped. They did not form a single orderly handover in which one institution finished its work and passed the molecule to the next. [1–7]

The historical record also leaves room for surprise. The meaning of MDMA was not contained in its patent. It developed as people encountered the molecule and interpreted what happened. [1–7]